## Yiyuan Yin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7697122/publications.pdf Version: 2024-02-01



Υίνιια Υινι

#	Article	IF	CITATIONS
1	LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor. Cell Metabolism, 2018, 27, 461-469.e6.	16.2	215
2	Crystal structure of a complete ternary complex of T-cell receptor, peptide–MHC, and CD4. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5405-5410.	7.1	108
3	The Multiple Mechanisms of T Cell Receptor Cross-reactivity. Immunity, 2009, 31, 849-851.	14.3	81
4	Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO Journal, 2011, 30, 1137-1148.	7.8	68
5	Structural basis for selfâ€recognition by autoimmune <scp>T</scp> â€cell receptors. Immunological Reviews, 2012, 250, 32-48.	6.0	68
6	Structural and Biophysical Insights into the Role of CD4 and CD8 in T Cell Activation. Frontiers in Immunology, 2013, 4, 206.	4.8	64
7	Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells. MAbs, 2017, 9, 213-230.	5.2	60
8	Affinity maturation of human CD4 by yeast surface display and crystal structure of a CD4–HLA-DR1 complex. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15960-15965.	7.1	47
9	Characterization of Chain Pairing Variants of Bispecific IgG Expressed in a Single Host Cell by High-Resolution Native and Denaturing Mass Spectrometry. Analytical Chemistry, 2016, 88, 12122-12127.	6.5	39
10	Identification of the Docking Site for CD3 on the T Cell Receptor Î <sup>2</sup> Chain by Solution NMR. Journal of Biological Chemistry, 2015, 290, 19796-19805.	3.4	36
11	Precise quantification of mixtures of bispecific IgG produced in single host cells by liquid chromatography-Orbitrap high-resolution mass spectrometry. MAbs, 2016, 8, 1467-1476.	5.2	33
12	Elucidating heavy/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells. MAbs, 2019, 11, 1254-1265.	5.2	19
13	Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity. Molecular Cancer Therapeutics, 2015, 14, 2270-2278.	4.1	6